| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1126884250 |
| P356 | DOI | 10.1111/JDV.16515 |
| P932 | PMC publication ID | 7264567 |
| P698 | PubMed publication ID | 32320091 |
| P2093 | author name string | A Conti | |
| L Naldi | |||
| P Gisondi | |||
| S Piaserico | |||
| P2860 | cites work | Age-dependent dysregulation of innate immunity | Q27022410 |
| Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice | Q33754820 | ||
| Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus | Q36872701 | ||
| Store-and-forward teledermatology versus in-person visits: a comparison in pediatric teledermatology clinic | Q39880869 | ||
| Impact of store-and-forward (SAF) teledermatology on outpatient dermatologic care: A prospective study in an underserved urban primary care setting | Q40338472 | ||
| Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology | Q45735792 | ||
| Teledermatology as a tool to improve access to care for medically underserved populations: A retrospective descriptive study. | Q46019537 | ||
| Implementation of a dermatology teletriage system to improve access in an underserved clinic: A retrospective study | Q50066161 | ||
| Pathogenicity and Viral Shedding of MERS-CoV in Immunocompromised Rhesus Macaques | Q50289951 | ||
| IL-17 boosts proinflammatory outcome of antiviral response in human cells | Q85027363 | ||
| Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts | Q87191021 | ||
| Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study | Q87412594 | ||
| COVID-19 and Italy: what next? | Q87701391 | ||
| New coronavirus outbreak: Framing questions for pandemic prevention | Q89109168 | ||
| 2019 Novel Coronavirus-Important Information for Clinicians | Q89545376 | ||
| Reducing mortality from 2019-nCoV: host-directed therapies should be an option | Q89606283 | ||
| Emergency management for preventing and controlling nosocomial infection of 2019 novel coronavirus: implications for the dermatology department | Q90101561 | ||
| Virtually Perfect? Telemedicine for Covid-19 | Q90238711 | ||
| History in a Crisis - Lessons for Covid-19 | Q90265547 | ||
| Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis | Q90337858 | ||
| On the front lines of coronavirus: the Italian response to covid-19 | Q90369573 | ||
| Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review | Q90404028 | ||
| Should patients stop their biologic treatment during the COVID-19 pandemic | Q90454620 | ||
| COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression | Q90496530 | ||
| Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia | Q90502868 | ||
| Coronaviruses and immunosuppressed patients. The facts during the third epidemic | Q90513524 | ||
| COVID-19 can present with a rash and be mistaken for Dengue | Q90658264 | ||
| Cutaneous manifestations in COVID-19: a first perspective | Q90677578 | ||
| COVID-19 cacophony: is there any orchestra conductor? | Q90719134 | ||
| The growth of teledermatology: Expanding to reach the underserved | Q91773377 | ||
| P921 | main subject | pandemic | Q12184 |
| SARS-CoV-2 | Q82069695 | ||
| P577 | publication date | 2020-04-22 | |
| 2020-06-01 | |||
| P1433 | published in | Journal of the European Academy of Dermatology and Venereology | Q15760872 |
| P1476 | title | Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice |
| Q103721213 | Azathioprine: its uses in dermatology |
| Q98242594 | Biologic drugs during COVID-19 outbreak |
| Q94581219 | COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management |
| Q100570772 | Change in Allergy Practice during the COVID-19 Pandemic |
| Q98195267 | Change of dermatological practice after the COVID-19 outbreak resolves |
| Q98242744 | Changing Trends in Dermatology Practice During COVID-19 Pandemic: A Single Tertiary Center Experience |
| Q97869183 | Comment on "Rescheduling of clinical activities and teleconsulting for public dermatology. Two prompt answers to COVID-19 emergency" |
| Q114801050 | Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue |
| Q98172133 | Dermatologic manifestations and complications of COVID-19 |
| Q101410118 | Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations |
| Q98614661 | Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults: A Systematic Review |
| Q104512985 | Impact of COVID-19 on nuclear medicine in the UK |
| Q103728261 | Impact of COVID-19 pandemic on the continuity of care for dermatologic patients on systemic therapy during the period of strict lockdown |
| Q104455787 | Impact of Paycheck Protection Program on dermatology practices during the COVID-19 pandemic |
| Q100728522 | Impact of covid-19 pandemic on dermatology practice: results of a web-based, global survey |
| Q99553715 | Impacts of COVID-19 on Dermatologic Practice, Disease Presentation, and Immunomodulator Prescriptions |
| Q101451680 | Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience |
| Q95285189 | Metastatic melanoma treatment with check point inhibitors in the COVID-19 era: experience from an Italian Skin Cancer Unit |
| Q96434299 | Modified mask for aesthetic procedures on face during COVID-19 era: chiseling our armamentarium |
| Q101150673 | Multicenter study evaluating the impact of COVID-19 outbreak on dermatology outpatients in Turkey |
| Q99202044 | National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1 |
| Q97079111 | Patch Testing During the COVID-19 Pandemic: Recommendations of the AEDV's Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) |
| Q96127359 | Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic |
| Q114255665 | Public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID‐19 pandemic: Insights from Google Trends |
| Q98937567 | Skin cancers: how to balance the risks and benefits of surgery during COVID-19 pandemic (a Northern Italy single-center experience) |
| Q96219919 | Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era |
| Q100546525 | Strategies to maximize clinical efficiency while maintaining patient safety during the COVID-19 pandemic: an interview-based study from private practice dermatologists |
| Q95846578 | Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during Covid-19 emergency in a tertiary center in Italy |
| Q103828585 | Telehealth Opportunities in the COVID-19 Pandemic Early Days: What Happened, Did Not Happen, Should Have Happened, and Must Happen in the Near Future? |
| Q101567138 | The challenge of concomitant infections in the coronavirus disease 2019 pandemic era: Severe acute respiratory syndrome coronavirus 2 infection in a patient with chronic Chagas disease and dimorphic leprosy |
| Q104264638 | The impact of COVID-19 pandemic on the management of patients with chronic urticaria: an observational two-center study from Turkey |
| Q96434480 | Therapeutic approach to skin reactions caused by personal protective equipment (PPE) during COVID-19 pandemic: An experience from a tertiary hospital in Granada, Spain |
Search more.